Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 4/20 | 0.71 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.49 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | MMP14 | P50281 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.42 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphonic Acid SCHEMBL10410285 | 0.93 | FDPS (0.63) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL515542 | 0.83 | FDPS (1.00) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL5451506 | 0.83 | FDPS (0.58) | FDPSGGPS1BTN3A1CA12CA2 | |
| Water SCHEMBL28274320 | 0.81 | FDPS (0.96) | FDPSGGPS1BTN3A1CA12CA2 | |
| Methyl Alcohol SCHEMBL9715289 | 0.80 | FDPS (0.93) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL5702824 | 0.76 | FDPS (0.63) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL8714524 | 0.76 | FDPS (0.63) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL6692428 | 0.76 | — | — | |
| SCHEMBL10247560 | 0.76 | AGER (0.62) | FDPSCYP19A1 | |
| SCHEMBL28381527 | 0.75 | FDPS (0.76) | FDPSGGPS1BTN3A1CA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2921172-B1 | Combination of an HMG-CoA reductase inhibitor and a farnesyl-pyrophosphatase synthase inhibitor for the treatment of diseases related to the persistence and/or accumulation of prenylated proteins | UNIV AIX MARSEILLE (FR) | 2018-09-12 | — | — | EP | disclosed |
| EP-2234620-B1 | TRITHERAPY USED TO TREAT A PATIENT INFECTED BY HIV | UNIV AIX MARSEILLE (FR) | 2016-03-09 | — | — | EP | disclosed |
| EP-2921172-A1 | Combination of an HMG-CoA reductase inhibitor and a farnesyl-pyrophosphatase synthase inhibitor for the treatment of diseases related to the persistence and/or accumulation of prenylated proteins | Universite d'Aix Marseille (FR) | 2015-09-23 | — | — | EP | disclosed |
| EP-2252282-B1 | COSMETIC AND/OR DERMATOLOGICAL COMPOSITION COMPRISING AN HMG-CoA REDUCTASE INHIBITOR AND A FARNESYL-PYROPHOSPHATE SYNTHASE INHIBITOR | UNIV AIX MARSEILLE (FR) | 2015-07-15 | — | — | EP | disclosed |
| EP-2034985-B1 | COMBINATION OF AN HMG-COA REDUCTASE INHIBITOR AND A FARNESYL-PYROPHOSPHATASE SYNTHASE INHIBITOR FOR THE TREATMENT OF DISEASES RELATED TO THE PERSISTENCE AND/OR ACCUMULATION OF PRENYLATED PROTEINS | UNIV AIX MARSEILLE (FR) | 2015-05-06 | — | — | EP | disclosed |
| WO-2012071517-A3 | NOVEL CRYSTALLINE FORMS | THAR PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | WO | disclosed |
| EP-2225252-B1 | C2-C5-ALKYL-IMIDAZOLE-BISPHOSPHONATES | NOVARTIS AG (CH) | 2012-06-27 | — | — | EP | disclosed |
| WO-2012071517-A2 | NOVEL CRYSTALLINE FORMS | THAR PHARMACEUTICALS, INC. (US) | 2012-05-31 | — | — | WO | disclosed |
| EP-2252282-A2 | COSMETIC AND/OR DERMATOLOGICAL COMPOSITION | Université de la Méditerranée - Aix-Marseille II (FR) | 2010-11-24 | — | — | EP | disclosed |
| EP-2234620-A2 | COMPOSITION AND METHODS USED DURING ANTI-HIV TREATMENT | Université de la Méditerranée - Aix-Marseille II (FR) | 2010-10-06 | — | — | EP | disclosed |
| EP-2225252-A1 | C2-C5-ALKYL-IMIDAZOLE-BISPHOSPHONATES | Novartis AG (CH) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009115652-A2 | COMPOSITION AND METHODS USED DURING ANTI-HIV TREATMENT | UNIVERSITE DE LA MEDITERANNEE, AIX-MARSEILLE II (FR) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009112653-A2 | COSMETIC AND/OR DERMATOLOGICAL COMPOSITION | UNIVERSITE DE LA MEDITERRANEE, AIX-MARSEILLE II (FR) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009068567-A1 | C2-C5-ALKYL-IMIDAZOLE-BISPHOSPHONATES | NOVARTIS AG (CH) | 2009-06-04 | — | — | WO | disclosed |
| US-20090137808-A1 | PROCESS FOR MANUFACTURING BISPHOSPHONIC ACIDS | ALBEMARLE CORPORATION (US) | 2009-05-28 | — | — | US | disclosed |
| EP-2034985-A1 | COMBINATION OF AN HMG-COA REDUCTASE INHIBITOR AND A FARNESYL-PYROPHOSPHATASE SYNTHASE INHIBITOR FOR THE TREATMENT OF DISEASES RELATED TO THE PERSISTENCE AND/OR ACCUMULATION OF PRENYLATED PROTEINS | Université de la Méditerranée - Aix-Marseille II (FR) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008003864-A1 | COMBINATION OF AN HMG-COA REDUCTASE INHIBITOR AND A FARNESYL-PYROPHOSPHATASE SYNTHASE INHIBITOR FOR THE TREATMENT OF DISEASES RELATED TO THE PERSISTENCE AND/OR ACCUMULATION OF PRENYLATED PROTEINS | UNIVERSITE DE LA MEDITERRANEE AIX-MARSEILLE II (FR) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137808-A1 | PROCESS FOR MANUFACTURING BISPHOSPHONIC ACIDS | BPGM, PGM2, GYPA | FDPS 417/4885GGPS1 15/4885BTN3A1 3449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.